idiopathic membranous nephropathy
Conditions
Interventions
Treatment group:Hydroxychloroquine (HCQ)+tacrolimus (FK506)+hormone (P)
Control group:Placebo+tacrolimus (FK506)+hormone (P)
Sponsors
The Seventh Affiliated Hospital of Sun Yat sen University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1) Age:18-65 years old, regardless of gender or nationality; 2) Idiopathic membranous nephropathy (IMN) was diagnosed by two renal pathologists who read the films and ruled out secondary membranous nephropathy (SMN); 3) The clinical evaluation requires hormone combined immunosuppressive therapy, including: Moderate risk patients, with normal eGFR, have received = 3 months of ACEI and/or ARB treatment, and their blood pressure is controlled (75% of the records), there are still proteinuria>4 g/d (confirmed twice) or urine protein decrease = 50%, and PLA2Rab8g/d = 3 months, PLA2Ra>50RU/ml; 4)eGFR>30ml.min.1.73m2 5) Sign the written consent.
Exclusion criteria
Exclusion criteria: 1) Unable or unwilling to sign written consent; 2) Secondary MN (such as hepatitis B, SLE, drugs, malignant tumors, etc.) 3) Type 1 or type 2 diabetes can not be differentiated from diabetes nephropathy 4) Blood creatinine > 4mg/dl (353umol/L); 5) Pregnancy, lactation or contraception by unreliable means; 6) Before randomization, maintenance dialysis was>2 weeks and/or maintenance dialysis was expected to be>8 weeks; 7) Kidney transplantation or planned kidney transplantation; 8) Allergies or contraindications to planned drugs 9) Patients with psoriasis or porphyria; 10) Retinopathy; 11) Participated in other clinical trials and/or used the study drug within 4 weeks before screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission rate;Partial remission rate; | — |
Countries
China
Contacts
Public Contactzheng,zhihua
The Seventh Affiliated Hospital of Sun Yat sen University
Outcome results
None listed